MicroTransponder Inc Profile last edited on: 12/3/2020
CAGE: 4PJK4
UEI: N3WDS9WM91M4
Business Identifier: Neurostimulation devices to treat neurological diseases 
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
2802 Flintrock Trace
Austin, TX 75230
Austin, TX 75230
| (972) 227-1160 |
| info@microtransponder.com |
| www.microtransponder.com |
Location: Single
Congr. District: 32
County: Dallas
Congr. District: 32
County: Dallas
Public Profile
Spun out of the University of Texas at Dallas, MicroTransponder Inc. (MTI) is a medical device company having developed therapies to treat several neurological conditions to include Tinnitus and Stroke. Based on decades of neuroscience research, the firm operations are anchored in the Paired Vagus Nerve Stimulation System (Paired VNS System). The Paired VNS System has been developed to treat two separate neurological conditions. The first is the Serenity® System for the treatment of chronic tinnitus. The second is the Vivistim® System for treatment of post-stroke upper limb mobility issues.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
15-19Revenue Range
1.5M-2MVC funded?
YesPublic/Private
Privately HeldStock Info
----IP Holdings
10-14Awards Distribution by Agency
Most Recent SBIR Projects
| Year | Phase | Agency | Total Amount | |
|---|---|---|---|---|
| 2016 | 1 | NIH | $224,257 | |
| Project Title: An Adjunct to Prolonged Exposure Therapy for Treating Refractory Ptsd Patients | ||||
| 2013 | 2 | NIH | $5,044,621 | |
| Project Title: Targeted Neural Plasticity for the Treatment of Tinnitus | ||||
| 2013 | 1 | NIH | $225,043 | |
| Project Title: A Novel Adjunct To Physical Training To Improve Motor Recovery Following Stroke | ||||
| 2012 | 2 | NIH | $2,511,622 | |
| Project Title: Wireless Neurostimulation for the Relief of Chronic Neuropathic and Inflammatory | ||||
| 2010 | 1 | NIH | $286,398 | |
| Project Title: Enhancing Fear Extinction Using Vagus Nerve Stimulation | ||||
Key People / Management
Jordan Curnes -- Founder, President and COO
Frank McEachern -- Chief Executive Officer; Chief Financial Officer; General Counsel
Jean-Philippe (Jp) Allar -- Sr. VP of Sales and Marketing, International
Scott Armstrong
Larry Cauller -- Co-Founder
Navzer Engineer -- Chief Scientific Officer
Ravi Jain
Ravi Jain -- Director of Engineering
Will Rosellini -- Chairman of the Board
Brent Tarver
Richard L Weiner
Frank McEachern -- Chief Executive Officer; Chief Financial Officer; General Counsel
Jean-Philippe (Jp) Allar -- Sr. VP of Sales and Marketing, International
Scott Armstrong
Larry Cauller -- Co-Founder
Navzer Engineer -- Chief Scientific Officer
Ravi Jain
Ravi Jain -- Director of Engineering
Will Rosellini -- Chairman of the Board
Brent Tarver
Richard L Weiner
